# Study of Ataluren for Previously Treated Participants With Nonsense Mutation Duchenne/Becker Muscular Dystrophy (nmDBMD) in Europe, Israel, Australia, and Canada

> **NCT01557400** · PHASE3 · COMPLETED · sponsor: **PTC Therapeutics** · enrollment: 94 (actual)

## Conditions studied

- Duchenne Muscular Dystrophy
- Becker Muscular Dystrophy
- Dystrophinopathy

## Interventions

- **DRUG:** Ataluren

## Key facts

- **NCT ID:** NCT01557400
- **Lead sponsor:** PTC Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05-20
- **Primary completion:** 2018-01-19
- **Final completion:** 2018-01-19
- **Target enrollment:** 94 (ACTUAL)
- **Last updated:** 2020-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01557400

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01557400, "Study of Ataluren for Previously Treated Participants With Nonsense Mutation Duchenne/Becker Muscular Dystrophy (nmDBMD) in Europe, Israel, Australia, and Canada". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01557400. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*